E Fund Management Co. Ltd. Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

E Fund Management Co. Ltd. raised its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 32.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,997 shares of the company’s stock after buying an additional 2,436 shares during the period. E Fund Management Co. Ltd.’s holdings in Denali Therapeutics were worth $204,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. FMR LLC increased its stake in shares of Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after buying an additional 7,596,508 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Denali Therapeutics by 63.2% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Denali Therapeutics by 9.2% in the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after acquiring an additional 903,683 shares during the period. Fisher Asset Management LLC raised its stake in shares of Denali Therapeutics by 44.8% during the fourth quarter. Fisher Asset Management LLC now owns 792,499 shares of the company’s stock valued at $16,151,000 after acquiring an additional 245,168 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after purchasing an additional 149,939 shares during the period. 92.92% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on DNLI shares. Morgan Stanley assumed coverage on Denali Therapeutics in a report on Friday. They set an “overweight” rating and a $33.00 price target on the stock. William Blair restated an “outperform” rating on shares of Denali Therapeutics in a report on Friday, February 28th. JPMorgan Chase & Co. cut their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. Oppenheimer reduced their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Finally, Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Denali Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $37.27.

Denali Therapeutics Trading Up 2.6 %

DNLI stock opened at $16.69 on Monday. The stock’s 50 day simple moving average is $20.80 and its 200 day simple moving average is $24.30. Denali Therapeutics Inc. has a 12-month low of $14.01 and a 12-month high of $33.33. The stock has a market capitalization of $2.42 billion, a PE ratio of -6.05 and a beta of 1.46.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. On average, research analysts predict that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Activity at Denali Therapeutics

In other Denali Therapeutics news, CEO Ryan J. Watts sold 29,266 shares of the stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the transaction, the chief executive officer now owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Carole Ho sold 12,255 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $247,796.10. Following the sale, the insider now directly owns 178,580 shares of the company’s stock, valued at $3,610,887.60. The trade was a 6.42 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,940 shares of company stock worth $973,442 over the last quarter. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.